Expert recommendations for PIK3CA testing in HR+/HER2− locally advanced and metastatic breast cancer

npj Breast Cancer 2026 Open access

Read full text
Authors: Caterina Marchiò, Federico Rojo, Ellen R. Copson, Fernando Schmitt, Beatríz Bellosillo, Carlo Fremd
DOI: 10.1038/s41523-026-00968-3
Cited by: 1
References: 80

Abstract

PIK3CA mutations are common in HR+/HER2- metastatic breast cancer and guide the use of PI3K-targeted therapies. This expert consensus provides recommendations on timing, methods, and interpretation of PIK3CA testing, emphasizing early assessment at metastatic diagnosis, preferred use of NGS panels, and standardized pre-analytical workflows. Reflex and dual-sample strategies can reduce delays and failures. Implementation requires coordinated logistics, education across the diagnostic chain, and equitable access to ensure timely, personalized treatment.

Fields of Study & Subjects

PI3K/AKT/mTOR signaling in cancer Advanced Breast Cancer Therapies Lung Cancer Treatments and Mutations

Publication details

Journal / source
npj Breast Cancer
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Publication date
15 May 2026
Language
EN